Roche Wins Two French Early Access Programs In Breast Cancer
Roche's cancer drugs, Tecentriq (atezolizumab) and Kadcyla (trastuzumab emtansine), are the latest products to be granted French temporary use authorizations for new, as yet unapproved indications.
You may also be interested in...
Roche’s checkpoint inhibitor has been approved in combination with nab-paclitaxel in the EU for triple-negative breast cancer, cementing the company’s role as an innovator in breast cancer therapies.
This is a monthly update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Tecentriq has become the second authorized medicine to be made available for an unapproved indication under modifications to France’s early access program. Patients with small cell lung cancer can now be given the product pending EU approval of its use in this condition.